299. 嚢胞性線維症 Cystic fibrosis Clinical trials / Disease details

臨床試験数 : 1,696 / 薬物数 : 1,644 - (DrugBank : 272) / 標的遺伝子数 : 96 - 標的パスウェイ数 : 170

4 trials found

diseases per page:

Showing 1 to 4 of 4 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02807415 (ClinicalTrials.gov)	June 1, 2016	16/6/2016	ICM to Evaluate the Activation of p.Phe508del-CFTR by Lumacaftor in Combination With Ivacaftor	Intestinal Current Measurements (ICM) to Evaluate the Activation of Mutant CFTR in Subjects With Cys ...	Cystic Fibrosis	Drug: Lumacaftor plus Ivacaftor	Hannover Medical School	Heidelberg University;University of Giessen	Completed	6 Years	N/A	All	104		Germany
2	NCT01931839 (ClinicalTrials.gov)	October 2013	26/8/2013	A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older ...	A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor ...	Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation	Drug: Lumacaftor Plus Ivacaftor Combination;Drug: Ivacaftor	Vertex Pharmaceuticals Incorporated	NULL	Completed	12 Years	N/A	All	1164	Phase 3	United States;Australia;Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Ireland;Italy;N ...
3	NCT01807923 (ClinicalTrials.gov)	May 2013	4/3/2013	A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Ol ...	A Phase 3, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Effica ...	Cystic Fibrosis, Homozygous for the F508del CFTR Mutation	Drug: Lumacaftor Plus Ivacaftor Combination;Drug: Ivacaftor;Drug: Placebo	Vertex Pharmaceuticals Incorporated	NULL	Completed	12 Years	N/A	All	559	Phase 3	United States;Australia;Canada;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Sweden;United ...
4	NCT01807949 (ClinicalTrials.gov)	April 2013	4/3/2013	A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Ol ...	A Phase 3, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Effica ...	Cystic Fibrosis, Homozygous for the F508del CFTR Mutation	Drug: Placebo;Drug: Lumacaftor Plus Ivacaftor Combination;Drug: Ivacaftor	Vertex Pharmaceuticals Incorporated	NULL	Completed	12 Years	65 Years	All	563	Phase 3	United States;Australia;Austria;Belgium;Canada;Denmark;France;Germany;Spain;United Kingdom

First Previous1Next Last